Benserazide-d3 (hydrochloride)

• UNSPSC Description:

  Benserazide-d3 (hydrochloride) is the deuterium labeled Benserazide hydrochloride. Benserazide hydrochloride (Serazide) is commonly used in Parkinson's disease and is an inhibitor of peripheral aromatic L-amino acid decarboxylase (AADC)[1].

• Target Antigen:

  Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Others

• Field of Research:

  Neurological Disease

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C(C([2H])([2H])O)([2H])N)NNCC1=CC=C(C(O)=C1O)O.Cl

• Molecular Weight:

  296.72

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Shen H, et al. Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats. Tohoku J Exp Med. 2003 Mar;199(3):149-59.|[3]Chandel TI, et al. A multiparametric analysis of the synergistic impact of anti-Parkinson's drugs on the fibrillation of human serum albumin. Biochim Biophys Acta Proteins Proteom. 2019 Mar;1867(3):275-285.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported